PHARMACOKINETICS OF NEW CEPHALOSPORINS

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。不断需要新的抗生素来治疗抗生素耐药生物体的感染。头孢菌素需要在黑猩猩中进行生物利用度测试，因为人类和黑猩猩中存在限制可用性的血清结合蛋白。因此，在黑猩猩中进行的药代动力学研究预测了启动人体试验的抗生素水平。拟议的实验将包括在2只体重相似的同性黑猩猩身上测试4种新的头孢菌素化合物。化合物将以0.5 mg/kg的剂量每两周IV给予。每次给药将包括以下采血时间：0或给药前即刻，15分钟，30分钟，1小时，2小时，4小时，8小时。24小时将检测血浆样本的药物水平，以确定这些新药的药代动力学。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. New antibiotics are constantly needed to treat infections with antibiotic resistant organisms. Cephalosporins need to be tested for bioavailability in chimpanzees, because there is a serum binding protein in humans and chimpanzees that limits availability. Thus, a pharmacokinetic study in chimpanzees predicts the level of antibiotic with which to initiate human trials. The proposed experiment will involve testing of 4 new cephalosporin compounds in 2 same-sex chimpanzees of similar weight. Compounds will be given IV every two weeks at a dose of 0.5 mg/kg. each dosing will involve the following blood sampling times; 0 or immediately prior to the dose, 15 min., 30 min., 1 hr., 2 hrs., 4 hrs., 8 hrs. and 24 hrs. Plasma samples will be tested for drug levels to determine the pharmacokinetics of these new drugs.